期刊文献+

雷洛昔芬上调卵巢切除大鼠腰椎护骨素mRNA的表达

Raloxifene up-regulates the mRNA expression of osteoprotegerin in the lumbar vertebra of ovariectomized rats
下载PDF
导出
摘要 目的建立绝经后骨质疏松(postmenopausalosteoporosis,PMOP)的大鼠模型,研究雷洛昔芬(raloxifene,RLX)对卵巢切除大鼠腰椎组织中护骨素(OPG)基因mRNA表达水平的影响,探讨其治疗PMOP的作用机制。方法6月龄未交配健康雌性SD大鼠40只,随机分为假手术(SHAM)组,卵巢切除(OVX)组,OVX+戊酸雌二醇(E2)组和OVX+RLX组。灌胃13周后处死动物,第四腰椎行骨组织形态计量指标测定,第二腰椎采用RT-PCR方法,对OPGmRNA表达水平进行检测。结果OVX组大鼠较SHAM组骨小梁体积百分比(TBV%)显著下降;类骨质体积百分比(OSV%)明显升高(P<0.05);E2和RLX组大鼠的TBV%明显升高,OSV%明显下降;OPGmRNA表达水平在OVX大鼠组织中下调,与SHAM组相比有显著性差异(P<0.05),E2和RLX均可上调OVX大鼠骨组织OPGmRNA表达水平(P<0.05)。结论实验成功制造了大鼠PMOP模型;E2和RLX均可抑制骨转换;PMOP的发生与OPG有关,RLX和E2一样,其抗骨吸收效应很可能是通过OPG介导的。 Objective To establish a postmenopausal osteoporotic model of rats and investigate the effect of raloxifene(RLX) on the expression of OPG mRNA in lumbar vertebra of ovariectomizod rats, and to analyze its mechanism in the prevention of postmenopausal osteoporosis. Methods Forty female rats of 6-month-old were randomly allocated into 4 groups: sham operated group, ovariectomized group (OVX), ovariectomlzed + valerate estradiol group(OVX + E2 ), and ovariectomized + raloxifene group(OVX + RLX). All rats were sacrificed after lavaged for 13 weeks. The fourth lumbar vertebra was dissected for histomorphology and the second lumbar vertebra for measurement of OPG mRNA by reverse transcription polymerase chain reaction technique. Results The trabecular volume% was significantly lower in the OVX group than that in the SHAM group, while the ostoid seam% was significantly higher (P 〈 0.05). The trabecular volume% Was increased and ostoid seam% was reduced in OVX +E2 group and OVX + RLX group. Compared with the SHAM rats, the OPG mRNA level was decreased significantly in the OVX group ( P 〈 0.05), and E2 and RXL up-regulated the expression of OPG mRNA significantly ( P 〈 0.05). Conclusions The rat model of postmenopausal osteoporosis is successfully established. Valerate estradiol and RXL can inhibit bone turnover. OVX-induced bone loss is associated with OPG. Raloxifene, as well as valerate estradiol, might have anti-resorbtion effect on bone mediated by OPG.
出处 《中国骨质疏松杂志》 CAS CSCD 2006年第6期612-615,共4页 Chinese Journal of Osteoporosis
关键词 绝经后骨质疏松 大鼠 护骨素 雷洛昔芬 Postmenopausal osteopornsis Rat Osteoprotegerin Raloxifene
  • 相关文献

参考文献12

  • 1Riggs BL,Khosla S,Melton LJ 3rd.Sex steroid and the construction and conservation of the adult skeleton.Endocr Rev,2002,23:279-302.
  • 2Saika M,lnoue D,Kido S,et al.17beta-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line,ST-2,via estrogen receptor-alpha.Endocrinology,2001,142:2205-2212.
  • 3王宝利,郭若霖,左爱军,邱明才,张镜宇.破骨细胞分化因子和护骨素mRNA在OVX小鼠骨组织的相对表达[J].中华老年医学杂志,2003,22(10):608-611. 被引量:8
  • 4NIH Consensus Development Panel on Osteoporosis prevention,diagnosis,and therapy.JAMA,2001,285:785-795.
  • 5李宁华,区品中,朱汉民,杨定焯,郑蘋如.Prevalence rate of osteoporosis in the mid-aged and elderly in selected parts of China[J].Chinese Medical Journal,2002(5):773-775. 被引量:20
  • 6Boyle WJ,Simonet WS,Lacey DL.Osteoclast differentiation and activation.Nature,2003,423:337-342.
  • 7Bryant HU,Glasebrook AL,Yang NN,et al.An estrogen receptor basis for raloxifene action in bone.J Steroid Biochem Mol Biol,1999,69:37-44.
  • 8Viereck V,Grundker C,Blaschke S,et al.raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts.J Clin Endocrinol Metab,2003,88:4206-4213.
  • 9Cheung J,Mak YT,Papaioannou S,et al.Interleukin-6 (IL-6),IL-1,receptor activator of nuclear factor kappa B ligand (RANKL)and osteoprotegerin production by human osteoblastic cells:comparison of the effects of 17-beta oestradiol and raloxifene.J Endocrinol,2003,177:423-433.
  • 10Bord S,Horner A,Beavan S,et al.Estrogen receptors alpha and beta are differentially expressed in developing human bone.J Clin Endocrinol Metab,2001,86:2309-2314.

二级参考文献13

  • 1Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell, 1998, 93: 165-176.
  • 2Burgess TL, Qian Y, Kaufman S, et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol, 1999, 145: 527-538.
  • 3Hofbauer LC, Khosla S, Dunstan CR, et al. Estrogen stimulate gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology,1999,140: 4367-4370.
  • 4Nemeth GG, Heydemann A, Bolander ME. Isolation and analysis of ribonucleic acids from skeletal tissues. Anal Biochem, 1989, 183: 301-304.
  • 5Kurebayashi S, Miyashita Y, Hirose T, et al. Characterization of mechanisms of IL-6 gene repression by estrogen receptor. J Steroid Biochem Mol Biol, 1997, 60:11-17.
  • 6Kimble RB, Bain S, Pacifici R, et al. The functional block of TNF but not of IL-6 prevents bone loss in ovariectomized mice. J Bone Miner Res, 1997, 12: 935-941.
  • 7Mieko Saika, Daisuke Inoue, Shinsuke Kido, et al. 17 beta-estradiol stimulates expression of osteoprotegerin by a mouses tromal cell line, ST2, via estragen receptor-α. Endocrinology, 2001, 142: 2205-2212.
  • 8Liao EY, Luo XH, Su X. Comparison of the effects of 17 beta-E2 and progesterone on the expression of osteoprotegerin in normal human osteoblast-like cells. J Endoerinol Invest,2002, 25: 785-790.
  • 9Srivastava S, Toraldo G, Weitzmann MN, et al. Estrogen decrease osteoclast formation by down regulating receptor activator of NF-κB ligand (RANKL)-induced JNK activation. J Biol Chem, 2001, 276: 8836-8840.
  • 10Cenci S, Weitzmann MN, Roggia C, et al. Estrogen deficiency induces bone loss by enhancing T cell production of TNF-α. J Clin Invest, 2000, 106: 1229-1237.

共引文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部